CRESCENT BIOPHARMA, INC.(CBIO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,916 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in CBIO
Events flagged as statistical outliers against CBIO's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-07-30
CBIO quality score dropped 15 points (28→13) on a new filing
View source filing →
CBIO Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for CRESCENT BIOPHARMA, INC. (CBIO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CBIO at 9.6/100 on a 32-signal composite quality model, placing it at rank #2,916 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue scale (0.4) and free cash flow (0.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), CRESCENT BIOPHARMA, INC. reports net income of $-24.8M, free cash flow of $-19.5M. Top institutional holders of CBIO by reported 13-F value include FMR, BVF, Fairmount Funds Management, based on the most recent SEC filings. CBIO trades on the Nasdaq exchange and files with the SEC under CIK 1253689. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CRESCENT BIOPHARMA, INC. directly from SEC EDGAR. CRESCENT BIOPHARMA, INC.'s 13F Pro composite quality score has ranged between 6 and 29 since 2026, currently 9.6 — a declining long-term trajectory across 47 quarterly and live scoring snapshots.
Revenue
Q2 2026
$0.00
Net Income
Q2 2026
$-24.8M
Free Cash Flow
Q2 2026
$-19.5M
ROIC
Q2 2026
-64.6%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
-306.4% YoYOperating Income
-281.2% YoYEPS (Diluted)
Total Assets
+574.7% YoYOp. Cash Flow
-130.0% YoYFree Cash Flow
-132.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $10.8M | — | $10.0K -86.7% | $75.0K -93.5% | $1.2M -88.6% | $10.2M |
| Net Income | $-153.9M -306.4% | $-37.9M -2.7% | $-36.9M +21.0% | $-46.7M +26.4% | $-63.4M -24.3% | $-51.0M |
| Operating Income | $-152.6M -281.2% | $-40.0M -1.9% | $-39.3M +17.1% | $-47.4M +25.3% | $-63.4M -23.2% | $-51.5M |
| EPS (Diluted) | — | $-0.29 -1.7% | $-0.29 +34.8% | $-0.45 +27.6% | $-0.61 -9.8% | $-0.56 |
| Total Assets | $240.3M +574.7% | $35.6M -21.4% | $45.3M -12.5% | $51.8M -45.1% | $94.3M -33.9% | $142.8M |
| Operating Cash Flow | $-71.5M -130.0% | $-31.1M +10.8% | $-34.9M +24.9% | $-46.5M +19.2% | $-57.5M -46.5% | $-39.2M |
| Free Cash Flow | $-72.5M -132.9% | $-31.1M +10.9% | $-34.9M +25.0% | $-46.5M +19.1% | $-57.5M -46.3% | $-39.3M |
Get alerted when CBIO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for CRESCENT BIOPHARMA, INC. including:
Top Institutional Holders of CBIO
FMR LLC
$74.4M4,133,514 shBVF INC/IL
$49.5M2,748,763 shFairmount Funds Management LLC
$49.5M2,747,866 shVR Adviser, LLC
$38.4M2,133,576 shLogos Global Management LP
$34.2M1,900,000 shFCPM III SERVICES B.V.
$30.2M1,677,852 shBALYASNY ASSET MANAGEMENT L.P.
$29.9M1,662,917 shVestal Point Capital, LP
$29.3M1,630,000 shOpaleye Management Inc.
$23.7M1,319,351 shBlackRock, Inc.
$22.9M1,271,762 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $74.4M | 4,133,514 |
| BVF INC/IL | $49.5M | 2,748,763 |
| Fairmount Funds Management LLC | $49.5M | 2,747,866 |
| VR Adviser, LLC | $38.4M | 2,133,576 |
| Logos Global Management LP | $34.2M | 1,900,000 |
| FCPM III SERVICES B.V. | $30.2M | 1,677,852 |
| BALYASNY ASSET MANAGEMENT L.P. | $29.9M | 1,662,917 |
| Vestal Point Capital, LP | $29.3M | 1,630,000 |
| Opaleye Management Inc. | $23.7M | 1,319,351 |
| BlackRock, Inc. | $22.9M | 1,271,762 |
Companies Similar to CBIO
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Dianthus Therapeutics, Inc. /DE/
Avalo Therapeutics, Inc.
uniQure N.V.
Zenas BioPharma, Inc.
OCULAR THERAPEUTIX, INC
NewAmsterdam Pharma Co N.V.
Monte Rosa Therapeutics, Inc.
Taysha Gene Therapies, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put CBIO on your watchlist
Track score changes the day CRESCENT BIOPHARMA, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CBIO a good stock to buy?
13F Pro's AI-powered analysis of CRESCENT BIOPHARMA, INC. (CBIO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CBIO are available on the CBIO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CBIO is classified as a small company.
Which hedge funds own CBIO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CBIO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CRESCENT BIOPHARMA, INC.'s investment landscape.